Transplantation of bone marrow stem cells during cardiac surgery

Sadeq Ali-Hasan-Al-Saegh1, Seyed Jalil Mirhosseini2, Mohammad-Reza Lotfaliani2

  • 1Cardiovascular Research Center, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran S.alihassan.cardiosurg@gmail.com.

Insights

Intramyocardial bone marrow stem cell transplantation during bypass surgery significantly improves left ventricular ejection fraction. This therapy is safe and effective for enhancing cardiac function post-surgery.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Surgery
  • Stem Cell Therapy

Background:

  • Coronary artery bypass graft (CABG) surgery is a common procedure for coronary artery disease.
  • Assessing novel therapeutic strategies to improve postoperative cardiac function is crucial.
  • Intramyocardial stem cell transplantation is being explored as an adjunct to CABG.

Purpose of the Study:

  • To evaluate the efficacy of intramyocardial bone marrow stem cell transplantation during CABG.
  • To assess the safety of this therapeutic approach.
  • To analyze the impact on key cardiac functional parameters: left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV).

Main Methods:

  • Systematic review and meta-analysis of relevant studies.
  • Comprehensive literature search across major databases (Medline/PubMed, Embase, Science, Google Scholar).
  • Inclusion of 9 studies with 335 patients, analyzing risk ratios and weighted mean differences for cardiac parameters.

Main Results:

  • Bone marrow stem cell transplantation demonstrated a significant increase in LVEF (WMD: 4.06, 95% CI: 0.41-7.72, p=0.02).
  • A nonsignificant reduction in LVEDV was observed (WMD: 7.06, 95% CI: -8.58-22.7, p=0.3).
  • No life-threatening complications were reported, indicating a favorable safety profile.

Conclusions:

  • Intramyocardial bone marrow stem cell transplantation is an effective method for improving cardiac function post-CABG.
  • The procedure significantly enhances LVEF.
  • The therapy is deemed safe, with no observed life-threatening adverse events.
Abstract